STOCK TITAN
  1. Home
  2. News
  3. NRBO

NeuroBo Pharmaceuticals Inc - NRBO STOCK NEWS

Welcome to our dedicated news page for NeuroBo Pharmaceuticals (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on NeuroBo Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroBo Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroBo Pharmaceuticals's position in the market.

News
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has submitted an IND application to the FDA for a Phase 1 clinical trial of DA-1726, a dual oxyntomodulin analog agonist for the treatment of obesity. The company aims to address the significant obesity market with a potential new treatment that has shown promising preclinical evidence of weight loss in animal models. The first dose is expected to be administered in the first half of 2024, with data readout anticipated in the first half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.24%
Tags
clinical trial
-
News
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) announces a 1-for-8 reverse stock split, reducing outstanding shares from 38.8 million to approximately 4.85 million. The split will be effective on December 21, 2023, to comply with Nasdaq's listing requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
511.61%
Tags
none
-
News
NeuroBo to Participate in Investor Conferences in December
Rhea-AI Summary
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company (Nasdaq: NRBO), announced that its executives will present updates on its cardiometabolic assets, DA-1241 and DA-1726, at two investor conferences in December. The company's focus on transformation of cardiometabolic diseases will be highlighted at the Investor Summit Virtual Conference on December 7 and the Life Science Virtual Investor Forum on December 14. Interested investors can register through the Life Science Virtual Investor Forum platform. The live webcast and archived replay of both presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences
News
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) announced financial results for Q3 2023, with cash and cash equivalents of $25.8 million expected to fund operations through Q4 2024. The company provided updates on the clinical development of their cardiometabolic assets, including the Phase 2a clinical trial of DA-1241 for NASH and preclinical testing results of DA-1726 for obesity. They also highlighted the appointment of James P. Tursi, M.D. to the Board of Directors and the out-licensing agreement with MTHERA for NB-01.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
earnings
-
News
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. has appointed James P. Tursi, a pharmaceutical industry veteran, to its Board of Directors. Dr. Tursi brings nearly 20 years of experience in the pharmaceutical industry and over 30 years of medical experience. He will provide valuable expertise as the company advances the clinical development of its cardiometabolic assets. NeuroBo is currently developing DA-1241, a novel GPR119 agonist, for the treatment of NASH, and DA-1726, a novel GLP1R and GCGR dual agonist, for obesity. Dr. Tursi's appointment is expected to drive shareholder value and maximize the potential of NeuroBo's next-generation pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
management
-
News
NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference
Rhea-AI Summary
NeuroBo Pharmaceuticals to present at H.C. Wainwright 7th Annual NASH Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences
News
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
Rhea-AI Summary
NeuroBo Pharmaceuticals begins Phase 2a trial of DA-1241 for NASH treatment, with potential interim analysis in H1 2024 and full data readout in H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.94%
Tags
clinical trial
-
News
NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT
Rhea-AI Summary
NeuroBo Pharmaceuticals, Inc. (NRBO) appoints Hyung Heon Kim as CEO and President, leveraging his expertise in advancing DA-1241 and DA-1726, potential therapies for NASH, obesity, and type 2 diabetes. Kim's deep familiarity with the assets and strong working relationship with partner Dong-A positions NeuroBo for clinical development and market leadership in cardiometabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
management
-
News
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
NeuroBo Pharmaceuticals announces progress in cardiometabolic assets, including FDA approval for DA-1241 and positive preclinical data on DA-1726. Signed term sheet with MTHERA for out-licensing of NB-01. Cash and Cash Equivalents of $28.7 million expected to fund operations into 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.21%
Tags
earnings
News
NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.18%
Tags
clinical trial
Stock NRBO logo
NeuroBo Pharmaceuticals Inc

Nasdaq:NRBO

NRBO Rankings

#6663 Ranked by Market Cap
#5499 Ranked by Stock Gains
N/A Ranked by Dividends

NRBO Stock Data

17.71M
4.71M
61.67%
1.37%
1.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About NRBO

neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.